Neurogenic's proprietary reagents and diagnostic assay are protected by a series of worldwide issued patents and pending patent applications.
Autoimmune system and schizophrenia:
Schizophrenia is a severe, chronic and debilitating mental disorder. The global adult prevalence is approximately 1%, however schizophrenics constitute close to 10% of the permanently disabled population in developed and developing countries. The onset of the disease is generally during adolescence, while its etiology remains elusive. In the 1990's Prof. Meir Shinitzky* and Dr. Michael Deckmann* from the Weizmann Institute of Science in Israel proposed an autoimmune etiology in at least one distinct group of patients in which early-onset schizophrenia originates from a peripheral autoimmune reaction against platelets mediated by Platelet-Associated Antibodies (PAA). As long as the blood-brain-barrier (BBB) remains intact, the autoimmune anti-platelet reaction will only affect the platelet counts, like in other autoimmune reactions against platelets (e.g. thrombocytopenia purpura); the disease, however, will remain dormant as far as mental aberrations are concerned. It is hypothesized that upon permeation of the BBB (e.g. upon injury, mental stress or viral infection) the anti-platelet autoantibodies will penetrate the brain and cross react with the dopamine receptors, displaying sharp mental deviations characteristic of schizophrenia. Based on this ground-breaking research, Neurogenic Ltd. was founded to translate this innovative approach to diagnosis of schizophrenia into an analytical diagnostic assay.